Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (10835)	7/17/1999 4:38:00 PM
From: aknahow	Respond to of 17367

Your on a roll but I still think that few are going to try to develop a "placebo special" for treating cancer. The cost would still be considerable, to demonstrate that it was safe and all the competition would be able to show that efficacy was lacking. Just because the FDA would not be involved in efficacy does not mean that the data on effect from any trial for safety would not be available for peer publication. So the world would know if a drug worked or not and could make their own decisions on a drug that was safe but worked marginably. If the FDA was free to spend its resources on safety only, who's to say more time would not be spent on drug interaction. At any rate Cacaito we will see what happens to the biotech industry.